Biden’s plan is to streamline decisions made by the FDA, NIH and other government agencies to both speed up drug approvals and give patients the freedom to obtain the combination of medicines that works best for them. He wants to increase tax incentives and patent protection for private companies to partner with and invest in government cancer research.

That has potential. But then this:

Clinton wants a vast new bureaucracy that would delay and limit such choices.

Clinton is planning to use a series of executive actions to control the price of cancer drugs, how they are used and who will get them. There is nothing Congress or the courts can do, short of replacing ObamaCare, to change that.

She strongly supports a Centers for Medicare and Medicaid Services experiment to randomly pay some doctors a lower fee when they use more expensive drugs for cancer and other complex illnesses to see if it saves money.

And she’s proposing even more repression.